• By ICR Secretariat
  • Posted Thursday, July 13, 2023

FDA grants Eisai’s Leqembi full approval, opening door to wider use of Alzheimer’s drug

https://www.biopharmadive.com/news/eisai-fda-leqembi-full-approval-alzheimers-coverage/685275/

On Thursday, the Food and Drug Administration awarded a full approval to the Alzheimer’s disease treatment Leqembi, a decision expected to significantly increase use of the therapy and, potentially, others that work like it.